Clinical Watch: August 2019

September 24, 2019

In this issue of Clinical Watch, we discuss the expanded indication for drugs to treat relapsing forms of multiple sclerosis. We suggest criteria for the relaunched IBS-C drug Zelnorm™ and review a clinical trial of a potentially disease-modifying sickle cell disease treatment. Finally, we review claims data to identify patients at risk for a fall.

For more information about a specific topic, please contact Janelle Sheen or Karen Powell. Be sure to stay tuned for future monthly updates. For more information about our solutions, please visit conduent.com/pharmacy solutions. 

Previous Article
Best Moments from Milwaukee’s ISM 2019 Annual Conference
Best Moments from Milwaukee’s ISM 2019 Annual Conference

Next Article
The Role of Pharmacists in Fighting Substance Abuse
The Role of Pharmacists in Fighting Substance Abuse

Learn how community pharmacists can be an agents of change in the fight against substance abuse.

Explore our Clinical Watch Newsletter

Learn More